Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2024-05-29 Regulatory Filings
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 29, 2024, by Zura Bio Limited. It includes a Regulation FD Disclosure referencing a press release attached as Exhibit 99.1. The document is a current report on Form 8-K, which is used for unscheduled material events or corporate changes that are important to shareholders. The text does not contain detailed financial statements or comprehensive financial data, but rather a notification of a press release and regulatory disclosure. The document length is 4017 characters, which is relatively short and consistent with a regulatory filing rather than a full financial report. Therefore, this document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2024-05-29 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated May 24, 2024, for Zura Bio Limited. It is a preliminary prospectus related to the resale of Class A Ordinary Shares by selling securityholders. The text includes detailed information about the securities being registered, the selling securityholders, the plan of distribution, risk factors, use of proceeds, management discussion and analysis, business description, management, executive compensation, principal shareholders, and legal matters. This type of filing is used for registering securities for public offering and is not a financial report, earnings release, or management discussion standalone. It is a capital markets filing related to financing and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or a brief notice, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2024-05-24 English
Director's Dealing 2024
Director's Dealing
2024-05-23 English
FORM 10-Q/A
Interim / Quarterly Report Q1 2024
2024-05-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2024, by Zura Bio Limited. It announces the issuance of a press release regarding the company's first quarter 2024 financial results. The document explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the information is not deemed "filed" for certain regulatory purposes. The document itself does not contain the financial results or detailed financial statements but rather announces the release of such information. The length of the document is 3959 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit into other specific categories like Earnings Release or Interim Report, which would require substantive financial data within the document itself.
2024-05-09 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.